The Australian stock exchange today granted a request from GI Dynamics (ASX:GID) to halt trading in shares of its stock, pending a company announcement between now and March 9.
Bariatrics
Disinfection robots, Google Glass, artificial pancreas top hospitals’ tech list
Obalon Therapeutics gets $30m for weight-loss balloon
Weight loss: FDA approves EnteroMedics Maestro obesity device
Weight loss: ReShape Medical’s Duo balloon system looks to curb obesity
GI Dynamics proposes 1-for-10 reverse stock split
Diabetes: Better remission after weight loss surgery than other methods
NEW YORK (Reuters Health) – More than 20 years of evidence suggests that bariatric surgery produces greater weight loss and more type 2 diabetes remissions than nonsurgical treatments for the obese, according to a review.
GI Dynamics shares plunge on EU sales halt for EndoBarrier device
Diabetes improvements remain 3 years after bariatric surgery, Ethicon reports
Patients in a clinical study who had bariatric surgery saw sustained improvements in symptoms of Type II diabetes out to 3 years after the procedure, some reporting complete diabetes remission, researchers said.
Weight loss: GI Dynamics raises $32M with private placement
GI Dynamics (ASX:GID) said it raised about $31.7 million (A$34.3 million) in a private placement with a group of "sophisticated, professional and accredited investors" overseas.
ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.